title: [Prognostic value of hemoglobin level for primary radiochemotherapy of head-neck carcinomas].
abstract: The pretherapeutic hemoglobin level (Hb) has been postulated to constitute a prognostic marker for outcome after primary chemoradiation of patients with advanced cancer of the head and neck. However, this hypothesis has not been tested systematically in large study samples. In the years 1992-1997, 125 patients with advanced head and neck cancer (stages III/IV UICC) were treated with primary chemoradiation in two different prospective multicentric trials, 62 patients in trial A (phase II, 1992-1995), and 63 in trial B (phase III, 1995-1997). Beside initial Hb, other pretherapeutic parameters with potential prognostic relevance were assessed and correlated with clinical outcome after 43-months follow-up: total tumor volume (TTV; calculated in initial CT scans), tumor oxygenation (polarographic measurements with Eppendorf histography), TNM, tumor localization, age, and performance status. The evaluation of the clinical end points (progression-free and overall survival and local tumor control) revealed that Hb and TTV were independent parameters with strong predictive character of outcome after primary chemoradiation in both trials (n = 125). Bivariate analysis showed < median (13.5 g/dl) a hazard ratio of 2.1 (P = 0.002) for Hb; and > median (98 ml) a Hazard ratio of 2.0 (P = 0.006) for TTV. Severe anemia (Hb < 10 g/dl) was an adverse factor in three patients. Hypoxia was associated with poorer initial therapeutical response but was not predictive of clinical outcome. Furthermore, tumor oxygenation showed no correlation with Hb. The other parameters examined failed to show prognostic significance. Our results indicate a high prognostic value of initial Hb for outcome after primary chemoradiation in advanced head and neck cancer and imply a therapeutic benefit of Hb substitution or erythropoietin administration. We propose to test this in randomized clinical trials.
authors.affiliation: Hals-Nasen-Ohren-Universitätsklinik Heidelberg. Andreas_Dietz@med.uni-heidelberg.de
authors.forename: A
authors.initials: A
authors.lastname: Dietz
authors.forename: V
authors.initials: V
authors.lastname: Rudat
authors.forename: C
authors.initials: C
authors.lastname: Conradt
authors.forename: B
authors.initials: B
authors.lastname: Vanselow
authors.forename: P
authors.initials: P
authors.lastname: Wollensack
authors.forename: S
authors.initials: S
authors.lastname: Staar
authors.forename: H
authors.initials: H
authors.lastname: Eckel
authors.forename: P
authors.initials: P
authors.lastname: Volling
authors.forename: M
authors.initials: M
authors.lastname: Schröder
authors.forename: M
authors.initials: M
authors.lastname: Wannenmacher
authors.forename: R P
authors.initials: RP
authors.lastname: Müller
authors.forename: H
authors.initials: H
authors.lastname: Weidauer
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate